ArticleCureus2026
Primary Diffuse Large B-cell Lymphoma of the Urinary Bladder: A Case Report and Narrative Review of Treatment Modalities and Clinical Outcomes.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary diffuse large B-cell lymphoma (DLBCL) of the urinary bladder is a rare extranodal lymphoma, representing a very small proportion of both bladder malignancies and extranodal lymphomas. We report a 73-year-old, chronically institutionalized woman with Eastern Cooperative Oncology Group (ECOG) 3-4 who presented with abdominal/flank pain, fever, hydronephrosis, and polymicrobial urosepsis. A bladder mass was detected incidentally on CT and subsequently confirmed by cystoscopy and transurethral resection of bladder tumor (TURBT). Histopathology showed a CD20-positive, CD5/CD10-negative large B-cell lymphoma (BCL) with Ki-67 of 50% (focally up to 80%), multiple myeloma oncogene (MUM)-1 positivity, and an isolated BCL6 rearrangement without concurrent myelocytomatosis oncogene (MYC) or BCL2 abnormalities, consistent with a high-grade, non-GCB DLBCL. Given her frailty and comorbidities, she was treated with rituximab monotherapy followed by involved-site radiotherapy instead of anthracycline-based chemoimmunotherapy, achieving marked metabolic and anatomic regression of the bladder lesion on positron emission tomography (PET)/CT. We present a narrative review of the literature on primary bladder DLBCL, highlight diagnostic and therapeutic considerations in the context of severe frailty, and discuss how de-escalated, organ-preserving strategies may be appropriate for selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.